Teva paid $40.5 billion for Allergan's generics business in 2016. By mid-2026 its net debt had fallen to $12.9 billion, and its 2027 target is leverage below 2 times EBITDA.
Teva Pharmaceutical Industries paid $40.5 billion for Allergan's generics business, a deal that closed in August 2016 and loaded the company with debt for a decade. By June 30, 2026, Teva's net debt had fallen to $12.9 billion, or 2.8 times EBITDA, according to its second-quarter results. The next test is its 2027 target of net debt below 2 times EBITDA.
How did the Allergan deal go wrong?
The Allergan generics deal went wrong because Teva paid a peak price for a US generics business just as generic pricing began to compress. Allergan received $33.4 billion in cash plus 100.3 million Teva shares when the deal closed on August 2, 2016, according to Allergan's SEC filing, and Teva put the total at $40.5 billion.
Teva, Israel's largest pharmaceutical company, headquartered in Petach Tikva, entered 2016 as the global leader in generics under then-CEO Erez Vigodman. By the end of 2017 it had written down about $17 billion of acquired goodwill, and its share price had collapsed. US wholesaler concentration and new direct-manufacturing competition pushed generic prices down, and net debt peaked at roughly $35 billion.
Multiple credit downgrades followed. The US opioid litigation, which touched Teva's fentanyl patches and other controlled-substance generics, added a multibillion-dollar liability layer.
What did the Schultz era change?
The Schultz era turned Teva from a growth-by-acquisition story into a deleveraging story. Kåre Schultz, the former Lundbeck CEO, took over in November 2017 and ran a textbook playbook: roughly 14,000 layoffs, asset sales, plant closures and tighter working capital.
Net debt fell steadily under his tenure, and the opioid litigation settled for about $4.25 billion, less than analysts had feared. Branded drugs became the growth engine: Austedo for Huntington's chorea and tardive dyskinesia, and Ajovy for migraine prevention.
What is the Francis pivot to growth?
The Francis pivot to growth is Teva's strategy of leading with innovative drugs and biosimilars instead of running the deleveraging playbook alone. Richard Francis, the former Sandoz CEO, succeeded Schultz in January 2023 with three pillars: deliver on branded drugs, scale biosimilars and keep financial discipline.
The results now show up in the numbers. In the second quarter of 2026, Austedo, Ajovy and Uzedy revenue grew a combined 43% year over year, and Teva raised its 2026 outlook for all three, according to the company's earnings call on July 29, 2026. Teva guides to $2.45 billion to $2.6 billion of Austedo revenue for 2026, and Francis said Austedo is approaching its $2.5 billion 2027 target ahead of schedule.
| Metric | Figure | Source |
|---|---|---|
| Net debt, June 30, 2026 | $12.9 billion | Teva Q2 2026 results |
| Net debt to EBITDA | 2.8x (2.3x excluding MLX) | Teva Q2 2026 results |
| Gross debt, June 30, 2026 | $16.6 billion | Q2 2026 earnings summary |
| 2026 revenue guidance | $16.5 to $16.85 billion | Teva Q2 2026 call |
| Generics revenue, Q2 2026 | Down 15% year over year | Q2 2026 call summary |
| 2027 leverage target | Net debt to EBITDA below 2x | Teva Q2 2026 call |
What does the remaining capital structure look like?
Teva's remaining debt is $16.6 billion gross and $12.9 billion net as of June 30, 2026, and management said Fitch has upgraded the company to investment grade. No amounts were drawn on its $1.8 billion revolving credit facility at quarter-end.
Risks remain. Generics revenue fell 15% year over year in the second quarter, mainly from losing generic Revlimid, and Teva booked a $724 million charge tied to the Emalex acquisition that produced a GAAP net loss of $576 million. Management also flagged pricing pressure from the US Inflation Reduction Act. Teva's revenue mix of branded, biosimilar and generic products is more diversified than at the deal peak, but it is still exposed to US generic pricing.
What does Teva mean for Israel?
Teva matters to Israel as its largest pharmaceutical employer and one of the country's biggest manufacturers. It trades on the New York Stock Exchange (TEVA) and on the Tel Aviv Stock Exchange, and its collapse after the Allergan deal was among the largest value-destruction events in Israeli public-equity history.
For Israeli institutional investors such as Mivtachim, Menorah, Migdal, Harel and Phoenix, Teva's deleveraging has been the largest single position-management challenge since 2016. The institutional read now is that Teva is no longer a turnaround story but a normal pharmaceutical position with a defined recovery path and a viable innovative pipeline.
What is the structural read on Teva?
Teva is the institutional case study in Israeli M&A overreach, and the deleveraging has been competently executed. The growth pivot is working in branded drugs but is not yet proven across the whole company, because generics are shrinking at the same time.
The next milestones are the 2027 targets Teva has set itself: net debt below 2 times EBITDA and a 30% non-GAAP operating margin. Hitting both would mark the formal end of the post-Allergan cycle.
Related from The Olam: Israeli health and biotech, TASE Foreign Ownership: $19.2B Held and Ackman's Stake, who owns the TASE and Israeli fintech and public markets.
Frequently asked questions
What did Teva buy in 2016?
Teva bought Allergan's generics business in a deal valued at $40.5 billion that closed on August 2, 2016. Allergan received $33.4 billion in cash and 100.3 million Teva shares.
Who led Teva's deleveraging?
Kåre Schultz led Teva from November 2017 and ran the deleveraging playbook of layoffs, divestitures and plant closures. Richard Francis succeeded him in January 2023 and introduced the Pivot to Growth strategy.
How much net debt does Teva have now?
Teva reported net debt of $12.9 billion at June 30, 2026, a net debt to EBITDA ratio of 2.8 times, according to its second-quarter 2026 results.
What is Teva's next financial milestone?
Teva targets net debt to EBITDA below 2 times and a 30% non-GAAP operating margin by 2027, according to management on its July 2026 earnings call.
How we report: Olam stories draw on public filings, company disclosures and named sources, checked by our editors. Read our methodology · Corrections
